<SEC-DOCUMENT>0001193125-16-635901.txt : 20160629
<SEC-HEADER>0001193125-16-635901.hdr.sgml : 20160629
<ACCEPTANCE-DATETIME>20160629112456
ACCESSION NUMBER:		0001193125-16-635901
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160629
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160629
DATE AS OF CHANGE:		20160629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		161737786

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d221150d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): June&nbsp;29, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-26642</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>87-0494517</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>320 Wakara Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Salt Lake City, Utah 84108 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (801)&nbsp;584-3600 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2016, Myriad Genetics, Inc.
(&#147;Myriad&#148; or the &#147;Company&#148;) issued a press release relating to Myriad&#146;s myChoice HRD test successfully identifying patients that meet primary endpoint in TESARO&#146;s pivotal phase 3 ovarian cancer study with Niraparib. A
copy of the press release is furnished as Exhibit&nbsp;99.1 to this Current Report on Form 8-K and incorporated herein by reference. The press release will also be available under the &#147;Investors &#150;News Releases&#148; section of
Myriad&#146;s website at <U>www.myriad.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exhibit 99.1 may contain &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to our business, goals, strategy and financial and operational outlook.&nbsp;These &#147;forward-looking statements&#148; are based on management&#146;s current expectations of future events and are subject to a number
of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and
profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to
our new tests; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at
all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to
the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our
laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the
structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our
ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be
unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading &#147;Risk Factors&#148; contained in Item&nbsp;1A of our most
recent Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.&nbsp;All
information in the exhibits is as of the date of the exhibits, and Myriad undertakes no duty to update this information unless required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated June&nbsp;29, 2016.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exhibit(s) may contain hypertext links to information on our website or other parties&#146; websites. The information on
our website and other parties&#146; websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item&nbsp;7.01 and in Exhibit 99.1 shall not be deemed to be
&#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any
registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MYRIAD GENETICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June&nbsp;29, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ R. Bryan Riggsbee</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">R. Bryan Riggsbee</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT INDEX </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated June&nbsp;29, 2016.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d221150dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g221150m01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Media&nbsp;Contact:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ron&nbsp;Rogers</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">(908)&nbsp;285-0248</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>rrogers@myriad.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Investor&nbsp;Contact:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott&nbsp;Gleason</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">(801)&nbsp;584-1143</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>sgleason@myriad.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Myriad&#146;s myChoice<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HRD Test Successfully
Identifies Patients that Meet Primary </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Endpoint in TESARO&#146;s Pivotal Phase 3 Ovarian Cancer Study with Niraparib </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>myChoice HRD Increases Eligible Patients by Approximately Twofold </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SALT LAKE CITY, Utah, June&nbsp;29, 2016</B> &#150;<U>Myriad Genetics</U>, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized
medicine, today announced that its myChoice<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HRD test successfully identified an increased number of patients with ovarian cancer who may benefit from treatment with niraparib. Niraparib is an
investigational oral PARP inhibitor being developed by TESARO (Nasdaq: TSRO). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Today&#146;s announcement follows results of the NOVA study
(NCT01847274), which evaluated the safety and efficacy of niraparib as a maintenance therapy in more than 500 patients with recurrent ovarian cancer. The primary outcome was the prolongation of progression-free survival (PFS). Patients were divided
into two groups: those with a germline<I> BRCA</I> mutation and those without. Patients without a germline<I> BRCA</I> mutation were evaluated for homologous recombination deficiency (HRD) using Myriad&#146;s myChoice HRD test. Patients in both
groups were randomized to receive niraparib or placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The study demonstrated that the myChoice HRD test approximately doubled the
number of patients who may benefit from niraparib treatment than identified by the current FDA-approved BRACAnalysis CDx<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> test. Importantly, patients who were germline BRCA negative, but
myChoice HRD positive, experienced over a threefold increase in median PFS with niraparib compared to placebo. The key findings are summarized in Table 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 1: NOVA Study Results </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:77.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Companion Diagnostic</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prolonged&nbsp;PFS&nbsp;Benefit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:79.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Niraparib&nbsp;vs.&nbsp;Placebo)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:27.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">P-Value</FONT></B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">myChoice HRD positive</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(germline
negative)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9.1 months</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(12.9 vs. 3.8 months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">P&lt;0.0001</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BRACAnalysis&nbsp;CDx&nbsp;positive</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(germline
positive)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15.5 months</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(21.0 vs. 5.5 months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">P&lt;0.0001</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;We are very excited about these strong clinical findings as they demonstrate a new paradigm
to personalize PARP inhibitor treatment,&#148; said Mark Capone, president and CEO, Myriad Genetics. &#147;We believe the myChoice HRD test is positioned to become the gold standard companion diagnostic for PARP inhibitors and will help physicians
confidently select safe and effective treatment plans for their patients.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The myChoice HRD test is being developed in parallel with
the clinical development of niraparib. The collaboration with TESARO began in March 2014 and includes several ongoing clinical trials in a variety of tumor types. myChoice HRD expands Myriad&#146;s portfolio of precision medicine tests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About myChoice<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HRD </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad&#146;s myChoice HRD test is the most comprehensive homologous recombination deficiency test to detect when a tumor has lost the ability
to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The myChoice HRD score is a composite of three proprietary technologies: loss of heterozygosity, telomeric
allelic imbalance and large-scale state transitions. Positive myChoice HRD scores, reflective of DNA repair deficiencies, are prevalent in all breast cancer subtypes, ovarian and most other major cancers.&nbsp;In previously published data, Myriad
showed that the myChoice HRD test predicted drug response to platinum therapy in certain patients with triple-negative breast and ovarian cancers.&nbsp;It is estimated that 1.4&nbsp;million people in the United States and Europe who are diagnosed
with cancers annually may be candidates for treatment with DNA-damaging agents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About BRACAnalysis
CDx<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BRACAnalysis CDx is an <I>in vitro</I> diagnostic device intended for
the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the <I>BRCA1</I> and <I>BRCA</I>2 genes using genomic DNA obtained from whole blood specimens.&nbsp;In December 2014, BRACAnalysis
CDx was approved by the FDA as a companion diagnostic for Lynparza&#153; (olaparib) for patients with advanced ovarian cancer who have had three or more lines of chemotherapy </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call and Webcast </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A conference
call will be held Thursday, June&nbsp;30, 2016, at 8:00 a.m. EDT to discuss the NOVA study results. The dial-in number for domestic callers is (800)&nbsp;786-5819. International callers may dial (303)&nbsp;223-0117. All callers will be asked to
reference reservation number 21814076. An archived replay of the call will be available for seven days by dialing (800)&nbsp;633-8284 and entering the reservation number above. The conference call, along with a slide presentation, also will be
available through a live webcast at <U>www.myriad.com</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Myriad Genetics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad Genetics Inc. is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with
pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions
across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets,
diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company&#146;s website:
<U>www.myriad.com. </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad, the Myriad logo, BART, BRAC<I>Analysis</I>, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk
Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign
countries. MYGN-F, MYGN-G </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995,
including statements related to the ability of the myChoice HRD test to identify an increased number of patients with ovarian cancer who may benefit from treatment with niraparib; the Company&#146;s excitement about these strong clinical findings
and their demonstration of a new paradigm to personalized PARP inhibitor treatment; the Company&#146;s belief that the myChoice HRD test is positioned to become the gold standard diagnostic for PARP inhibitors and will help physicians confidently
select safe and effective treatment plans for their patients; the development of myChoice HRD testing, including several ongoing clinical trials, with the clinical development of niraparib; and the Company&#146;s strategic directives under the
captions &#147;About myChoice HRD,&#148; &#147;About BRACAnalysis CDx,&#148; and &#147;About Myriad Genetics.&#148; These &#147;forward-looking statements&#148; are based on management&#146;s current expectations of future events and are subject to
a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that
sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays;
risks related to decisions or changes in governmental or private insurers&#146; reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms;
risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire
new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing
and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading &#147;Risk Factors&#148; contained in Item&nbsp;1A of our most recent Annual Report on Form 10-K for the fiscal year
ended June&nbsp;30, 2015, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">###
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g221150m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g221150m01.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M*4;=49N\97Z/\#HE.1FLS06@ H * "@ H * "@ H * "@ H * "@ H * "@
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M3%MQ39?J2@H * "@ H * "@ H * "@ H * "@ H * "@ H ,B@ H 6@ H *
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M7FHWL5SHLH+6\8;<I!.4*K_#@5V2E25-1@K-''"-5U'*;NCT #'%<YT"T %
M!GM0 4 % !0 4 % !0!%/!%=6\D,RAXI%*LIZ$&@"EI.@Z;H<3QZ?;"%7.YN
M22?Q-&X+38TJ #I0 4 % !0 ?2@#S?XE?\AG0?\ KH?_ $):J.S)ENCTBI*%
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%BT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#(\0>(M-\-6:W6IW'E1.X1<*6)/T%7"G*H[1(G4C
M35Y'$Z-\//+UF\\06^MO)!>QN\#1I\XW\@Y/7':MZE>\%!K8PIX?EFZB>YWN
MC3-/I5N["<-L /GKM<D<9(]37*=?0OT",3QA_P B;K'_ %ZO_*M*7QHSJ_ _
M0YKX/?\ (B1_]?$G\Q6V*_B&&#_@G::M_P @B\_ZX/\ ^@FN:/Q(ZGLSSWX(
M_P#(M:A_U]?^RBNO&?&CBP/\-^IZ9)_JV^AKC.X\G^#'_'WX@_ZZK_-J[L7M
M$X,%]L]5N8([FVE@E4-'(A1@>X(P:X4[:G?:^C/G"\O;[P?_ ,)%X64,4N7"
M*?;/4?5<"O7C%5>6IV/%E)T>:EW/<? VACP_X3LK,KB8KYDO^^W)_P /PKS:
MT^>;9ZM&G[.FHE+XF?\ (FR_]=D_G41W+EL:WA+_ )%+2_\ K@M2]QK8T=1_
MY!EW_P!<7_D:!G$_"G_D WO_ %\?^RBJEN3#8R/$\W]B?$NVU2]A9[0A2IQG
M@#!Q[@\TUK&P/25SN&\8^'5MO/\ [6M]N,X!^;\NM1RL?,CSF\U>36_'NE:D
M87BM'F1+?>,%E#<G\S5VLK$[M,],\3:,-=T&XL<A78;HR>S#I4)VU+:OH<5X
M0\7)H,9T'7E:U>!B$D<< >A_H:IJ^J)3MHSK;OQKX>L[<RMJD,F!D+&=S'\!
M2LQW1Y=KFKW>O>(+'4I8'ALWE"6P;NH89/ZU:5E8EN[/1]<U2_BOC#:RE%1@
MNU0,DE2V3GH.,?G6:+9O:5<R7>G1RRE3)N9&*]&*L5R/KC- %V@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#@/$VN:+J7
MBZW\(:KHTMVKE7$O158C((QSCU-=,(2C#VD78YJE2$IJE)7.NT^VL[+S+>UD
MP% _=;LB,8P !V%<,;<SUU.Z5^5*VB&:!C^RD8%B&9B"TOF9&X_Q?YQ6O4R6
MQIT 5K^.UET^XCO@IM&0B4.<#;WS35T]!.UM2CIL6AZ';266GFWM88B'>-6^
M[OZ$_6JDY2=V**C!61=N+BS:*>.>6/8@"R@MT#=,_6I2?0=UL9EE#X=\,/\
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M6MH[KE)%>1AQ@@'D?C@UG"?*VS24.9)&1%X;U=;>^+W$7VS4(T2XG&>/F.[
M_P!T@"M/:1T[(S]G+7NRU:^'[ZUM4LF>&2"&]2XB(79A,Y9=O;!SCZTG43=_
M(:IM*WF:LMA*^K37*A/+>U\D>N[)/]:S4M+&EM;F';>']1;1$T^;S(61XCYG
MVK>0%/)7CY>E:.:YKF:@^6S-SP_I\NEZ5':S!3(C,6<'/F$DG<?<]36<Y<TK
MEPCRQL:U24% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % 'S?>>%[W6?''CW6-%9UUW1+Z&YM-I/SCY]Z8[Y 'Y8[FL
MZ,G1HJJOYI7]+_U\K^1=6*J5/9OK%6];*W]=SU$>+;3QI\'-7U>UPCMIUPD\
M.<F*41G<O]1[$56*BHQO'9VM]X85MU8J6Z95\*>)++PE\#-(UF_W&&"T7")]
MYV+$*H^IK7$2:DDE=M)+[D8X>/-%]DW^;%76/BM/9KJ\6@:"EHP$HTR2:7[7
MLS]W?P@8CU''<9XJ)?NK\VMNW]=.O?H5%JHKQTOW_K^NI%J?Q3E_X1+0_%&E
MVT0TZ:^6UU..Y5C);9.&P00 0>Y!SD<52BO;0C?W9;/\OUOZ:,5VZ<W;WH[K
M^OE;\NA<^*WC^^\#:382:3;P7-]=RMA)D9U$2*2[84@\?+SZ9K/FM447MU_
MUC%.#GZ?U^!;\8^.7T/P%:Z[I445Q>:@84LHI 2KM)@@$ @GC/>KJ1E&LJ,=
MV[&=*2E2=2>R5V5-;\8^(CXIM?"'ARUTV76Q:"ZN[B]9UMXQT*JJ_,221W.
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M/1_#R6 B^T_86DF:Z$77:6X4MM__ %9XIU/W/\3IO;^N@4_WMN32^U_ZZ_\
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M7*Q3CS+T-"QN?M5HDC)Y<N!YD>X,8VQRI([BI:LRD[HLTAA0 4 % !0 4 %
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M/KKL/Q-\5G3#'YAN#K("*.^3MX(Z$'H:51>R^(=-^TV*7A_PMHNN_!WQ!::
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M_P#T M&_\&\O_P C4 'VOQ?_ - +1O\ P;R__(U !]K\7_\ 0"T;_P &\O\
M\C4 'VOQ?_T M&_\&\O_ ,C4 'VOQ?\ ] +1O_!O+_\ (U !]K\7_P#0"T;_
M ,&\O_R-0 ?:_%__ $ M&_\ !O+_ /(U !]K\7_] +1O_!O+_P#(U !]K\7_
M /0"T;_P;R__ "-0 ?:_%_\ T M&_P#!O+_\C4 'VOQ?_P! +1O_  ;R_P#R
M-0 ?:_%__0"T;_P;R_\ R-0 ?:_%_P#T M&_\&\O_P C4 'VOQ?_ - +1O\
MP;R__(U !]L\7_\ 0"T;_P &\O\ \C4 'VSQA_T M&_\&\O_ ,C4 'VSQA_T
M M&_\&\O_P C4 'VSQA_T M&_P#!O+_\C4 'VSQA_P! +1O_  ;R_P#R-0 ?
M;/&'_0"T;_P;R_\ R-0 ?;/&'_0"T;_P;R__ "-0 ?;/&'_0"T;_ ,&\O_R-
M0 ?;/&'_ $ M&_\ !O+_ /(U !]L\8?] +1O_!O+_P#(U !]L\8?] +1O_!O
M+_\ (U !]L\8?] +1O\ P;R__(U !]L\8?\ 0"T;_P &\O\ \C4 'VSQA_T
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1=USG=&F.WKGGICE"2MHC_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
